MANISH ZINZUVADIA: Open Payments
NPI 1063726966 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$315,783 in 351 payments from 10 companies in 2025. Trend: 2023 $189,510 · 2024 $238,981 · 2025 $315,783
Speaker / faculty: $226,872Honoraria: $27,225Travel & lodging: $26,895Consulting: $23,449Food & beverage: $11,240Education: $101
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 106 | $111,826 |
| Teva Pharmaceuticals USA, Inc. | 53 | $60,212 |
| Otsuka America Pharmaceutical, Inc. | 44 | $56,171 |
| Alkermes, Inc. | 73 | $45,998 |
| Axsome Therapeutics, Inc. | 24 | $17,134 |
| Luye Pharma (USA) Ltd. | 15 | $15,323 |
| ABBVIE INC. | 20 | $6,382 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $2,053 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $474 |
| Lundbeck LLC | 10 | $210 |
Products named: COBENFY, UZEDY, REXULTI, ABILIFY MAINTENA, ARISTADA, LYBALVI, Auvelity, ERZOFRI EXTENDED-RELEASE.
Industry payments across NY — which companies pay providers there.
